Session 2

Mutational discordance: the big challenge in personalized treatments – any solutions?

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The great challenge for oncologists treating patients who are developing or progressing with metastatic disease is to be able to offer a truly personalized and targeted therapy that can have an early and meaningful effect on the course of the disease. At present the known molecular markers are limited in their frequency and reliability in determining the use of newer chemotherapies. Professor Eng discusses the challenges faced in ensuring timely and effective treatments based on the molecular profile of the tumour and the potential role of real-time analysis of mutational changes in the tumour when progression occurs.

Original languageEnglish
JournalColorectal Disease
Volume20
Issue numberS4
Pages (from-to)49-51
Number of pages3
ISSN1463-1318
DOIs
Publication statusPublished - 1 May 2018
Event13th Scientific and Annual Meeting of the European Society of Coloproctology - Acropolis Palais des Congrès, Nice, France
Duration: 26 Sep 201828 Sep 2018
Conference number: 13
https://www.escp.eu.com/conference-and-events/escp-nice-2018/registration-and-fees

Conference

Conference13th Scientific and Annual Meeting of the European Society of Coloproctology
Number13
LocationAcropolis Palais des Congrès
CountryFrance
CityNice
Period26/09/201828/09/2018
Internet address

Fingerprint

Neoplasms
Drug Therapy
Therapeutics
Oncologists

Bibliographical note

Abstract no. P090

Cite this

@article{0bca0154d37d43278eb7f4be28cdf54e,
title = "Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions?",
abstract = "The great challenge for oncologists treating patients who are developing or progressing with metastatic disease is to be able to offer a truly personalized and targeted therapy that can have an early and meaningful effect on the course of the disease. At present the known molecular markers are limited in their frequency and reliability in determining the use of newer chemotherapies. Professor Eng discusses the challenges faced in ensuring timely and effective treatments based on the molecular profile of the tumour and the potential role of real-time analysis of mutational changes in the tumour when progression occurs.",
author = "Kousgaard, {Sabrina Just} and Kirk, {Karina Frahm} and Nielsen, {Hans Linde} and Ole Thorlacius-Ussing",
note = "Abstract no. P090",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/codi.14079",
language = "English",
volume = "20",
pages = "49--51",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",
number = "S4",

}

Session 2 : Mutational discordance: the big challenge in personalized treatments – any solutions? / Kousgaard, Sabrina Just; Kirk, Karina Frahm; Nielsen, Hans Linde; Thorlacius-Ussing, Ole.

In: Colorectal Disease, Vol. 20, No. S4, 01.05.2018, p. 49-51.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Session 2

T2 - Mutational discordance: the big challenge in personalized treatments – any solutions?

AU - Kousgaard, Sabrina Just

AU - Kirk, Karina Frahm

AU - Nielsen, Hans Linde

AU - Thorlacius-Ussing, Ole

N1 - Abstract no. P090

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The great challenge for oncologists treating patients who are developing or progressing with metastatic disease is to be able to offer a truly personalized and targeted therapy that can have an early and meaningful effect on the course of the disease. At present the known molecular markers are limited in their frequency and reliability in determining the use of newer chemotherapies. Professor Eng discusses the challenges faced in ensuring timely and effective treatments based on the molecular profile of the tumour and the potential role of real-time analysis of mutational changes in the tumour when progression occurs.

AB - The great challenge for oncologists treating patients who are developing or progressing with metastatic disease is to be able to offer a truly personalized and targeted therapy that can have an early and meaningful effect on the course of the disease. At present the known molecular markers are limited in their frequency and reliability in determining the use of newer chemotherapies. Professor Eng discusses the challenges faced in ensuring timely and effective treatments based on the molecular profile of the tumour and the potential role of real-time analysis of mutational changes in the tumour when progression occurs.

UR - http://www.scopus.com/inward/record.url?scp=85047893715&partnerID=8YFLogxK

U2 - 10.1111/codi.14079

DO - 10.1111/codi.14079

M3 - Journal article

VL - 20

SP - 49

EP - 51

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - S4

ER -